Signature Estate & Investment Advisors LLC Buys 1,385 Shares of Celgene Co. (CELG)

Signature Estate & Investment Advisors LLC increased its stake in shares of Celgene Co. (NASDAQ:CELG) by 1.1% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 128,883 shares of the biopharmaceutical company’s stock after purchasing an additional 1,385 shares during the period. Celgene accounts for 2.1% of Signature Estate & Investment Advisors LLC’s investment portfolio, making the stock its 12th largest position. Signature Estate & Investment Advisors LLC’s holdings in Celgene were worth $18,794,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of CELG. Capital Counsel LLC NY raised its holdings in shares of Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC raised its holdings in shares of Celgene by 0.6% in the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 11 shares in the last quarter. Savant Capital LLC raised its holdings in shares of Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 20 shares in the last quarter. TCI Wealth Advisors Inc. raised its holdings in shares of Celgene by 0.9% in the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after acquiring an additional 26 shares in the last quarter. Finally, Granite Investment Advisors LLC raised its holdings in shares of Celgene by 1.1% in the 2nd quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 29 shares in the last quarter. 79.74% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have weighed in on the company. Stifel Nicolaus set a $130.00 price target on Celgene and gave the company a “buy” rating in a report on Monday, January 8th. SunTrust Banks set a $127.00 price target on Celgene and gave the company a “buy” rating in a report on Monday, January 8th. Guggenheim reaffirmed a “buy” rating and issued a $147.00 price target on shares of Celgene in a report on Wednesday. Oppenheimer set a $166.00 price target on Celgene and gave the company a “buy” rating in a report on Monday, January 8th. Finally, Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a report on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $131.18.

Celgene Co. (NASDAQ CELG) opened at $106.00 on Friday. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The stock has a market capitalization of $83,460.00, a P/E ratio of 25.00, a P/E/G ratio of 0.68 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the company earned $1.58 EPS. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. analysts predict that Celgene Co. will post 6.68 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/13/signature-estate-investment-advisors-llc-buys-1385-shares-of-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply